Kumar 1998a.

Methods	Study design: parallel RCT Study duration: March 1996 to March 1997 Study follow‐up: 1 year
Participants	Country: USA Setting: single centre Inclusion criteria: DD kidney transplant recipients Number: treatment group 1 (26); treatment group 2 (24) Mean age ± SD (years): treatment group 1 (42.21 ± 18.82); treatment group 2 (44.22 ± 16.56) Sex (M/F): treatment group 1 (14/10); treatment group 2 (15/11) Exclusion criteria: not reported
Interventions	Treatment group 1 hATG (ATGAM): daily dose adjusted to maintain peripheral CD3 count between 50 to 100/µL Treatment group 2 OKT3: daily dose adjusted to maintain peripheral CD3 count between 50 to 100/µL Immunosuppression (both groups) CNI (CSA or TAC): started 5 to 7 days post‐transplant, troughs CSA: 250 to 300 ng/mL, TAC: 10 to 15 ng/mL PRED: does not reported MMF or AZA: dose not reported
Outcomes	Death Graft loss Acute rejection Infection
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Funding source not specified